Complete drug study data should be uploaded on EU's public database

02/7/2013 | Public Service Europe

Drugmakers and researchers should publish comprehensive findings from clinical studies on the public European Union database, writes the Labour Party's Glenis Willmott, a member of the European Parliament. Summaries may be influenced by bias and could inflate drugs' value, Willmott writes. Financial penalties should be used to enforce transparency, Willmott writes.

View Full Article in:

Public Service Europe

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA